MK-677 vs HGH: MK-677 (ibutamoren) is an oral pill that makes your own pituitary release more growth hormone; HGH (somatropin) is growth hormone itself, given by injection. HGH is an approved prescription medicine; MK-677 has never been approved. Where the two were compared directly, in children with growth hormone deficiency, HGH injections worked better. Both are banned in sport, and both share GH-type side effects such as fluid retention and higher blood sugar.

This page compares them point by point: how they work, how they’re taken, the doses studied, legal status, benefits, side effects and results. For MK-677 in depth, see our MK-677 (ibutamoren) review.

MK-677 vs HGH at a glance

MK-677 (ibutamoren) HGH (somatropin, recombinant GH)
What it is Ghrelin receptor agonist; makes the pituitary release GH Growth hormone itself
How it’s taken By mouth, once a day Injection under the skin
Needs a working pituitary? Yes; not expected to work without GH-producing cells No
Approved as a medicine? No Yes (for example, GH deficiency)
Growth in GH-deficient children 6.0–8.2 cm/year 10.6–11.1 cm/year
Main side effects Appetite, swelling, muscle pain, higher blood sugar; heart-failure signal in frail older adults Label warnings include fluid retention, glucose intolerance and diabetes, raised pressure in the skull, tumor risk
US legal status Not controlled; FDA treats products sold as MK-677 as unapproved drugs Prescription drug; distribution for non-medical use is a federal crime
Sport (WADA) Banned at all times (S2.2.4) Banned at all times (S2.2.3)

Sources: FDA 2024, NCT04614337, 21 U.S.C. § 333(e), FDA warning letter 2025, WADA 2026; details below.

MK-677

MK-677 (ibutamoren mesylate, also MK-0677 and LUM-201) activates ghrelin receptors on GH-producing cells in the pituitary and in the hypothalamus, which triggers GH release; GH then raises IGF-1 (FDA 2024). Because it works through your own pituitary, some GH production has to be left: it “would not be expected to increase circulating GH in individuals with absent pituitaries or severely damaged somatotrophs” (FDA 2024). It enhances the body’s own GH pulses: on 25 mg/day, mean 24-hour GH rose 97% in older adults, mainly through taller pulses (Chapman 1996). It is not approved as a medicine; as LUM-201 it is in a Phase 3 trial in children with GH deficiency (NCT06948214).

HGH

Human growth hormone (somatropin) is the hormone itself, made with recombinant DNA. FDA-approved GH products exist for GH deficiency in children and adults, and their labels carry warnings about tumor risk, glucose intolerance and diabetes, raised pressure in the skull (intracranial hypertension), fluid retention, thyroid and adrenal effects, and in children slipped capital femoral epiphysis and worsening scoliosis (FDA 2024). In the trials that compared it with ibutamoren, GH was given as injections under the skin (FDA 2024).

MK-677 vs HGH: route of administration

MK-677 is taken by mouth; the trials used tablets once a day (Nass 2008). HGH has to be injected. That convenience is the main reason ibutamoren was developed for children with GH deficiency: an expert quoted in the FDA’s review noted the “added advantage of being an oral tablet instead of an injection” (FDA 2024).

Dosage

The two can’t be converted into each other: MK-677 is dosed in milligrams and works through your pituitary, while GH is dosed in milligrams or international units of the hormone itself. Claims online that a given MK-677 dose “equals” a number of HGH units have no study behind them. For the record:

  • MK-677 in trials: 2 to 50 mg once a day in adults (25 mg/day most often), and 0.2 to 3.2 mg/kg/day in GH-deficient children (MK-677 dosage).
  • GH in the comparison trial: 0.3 mg/kg per week by injection in GH-deficient children (FDA 2024).

Frequency of use

MK-677 was given once a day in every trial; a single dose raises GH for about 24 hours (FDA 2024). How often GH is injected depends on the product and the prescriber.

Legality

  • HGH: a prescription medicine. In the US, knowingly distributing GH, or possessing it with intent to distribute, for any use other than an authorized medical treatment on a doctor’s order is a federal crime punishable by up to 5 years in prison, or 10 years if someone under 18 is involved (21 U.S.C. § 333(e)).
  • MK-677: not a controlled substance on the DEA list (DEA), but not approved; the FDA calls products sold as “MK-677 Ibutamoren” unapproved new drugs (FDA 2025). See is MK-677 legal?
  • Sport: WADA bans GH under S2.2.3 and GH secretagogues including ibutamoren under S2.2.4, both at all times (WADA 2026).

Benefits

What MK-677 has actually been shown to do in human trials:

  • Raise GH and IGF-1: GH 1.8-fold and IGF-1 1.5-fold after 12 months on 25 mg/day (Nass 2008).
  • Add fat-free mass: +1.1 kg vs −0.5 kg on placebo over 12 months, but without any change in strength or function (Nass 2008).
  • Increase deep and REM sleep in one small study (Copinschi 1997).
  • Speed up growth in GH-deficient children, less than GH injections (NCT04614337).

It did not reduce body fat, and it did not help Alzheimer’s disease or recovery after hip fracture (Sevigny 2008, Bach 2004). The older version of this page listed fat loss, faster healing, hair growth and “nootropic effects” as shared benefits; none of these has been shown for MK-677 in a human trial.

Side effects

Because both raise GH and IGF-1, they share a family of side effects. The FDA notes that adverse events known with GH therapy, such as high blood sugar and fluid retention, were also reported with ibutamoren, and that it is concerned the other GH-related risks may apply too (FDA 2024).

  • MK-677 in trials: increased appetite (67% vs 36% on placebo), mild leg swelling, muscle pain, higher fasting glucose and lower insulin sensitivity (Nass 2008); heart failure and higher blood pressure in frail older adults after hip fracture (Adunsky 2011).
  • Injected GH: edema, joint pain, carpal tunnel syndrome, gynecomastia and new impaired fasting glucose or diabetes in some people (Nass 2008), plus the label warnings above (FDA 2024).

The older version of this page said both were “safe” with only hunger, water retention and anxiety as side effects. That isn’t what the data show. Full details: MK-677 side effects.

MK-677 vs HGH results

The only head-to-head data come from children with GH deficiency. Over six months:

Trial MK-677 / LUM-201 GH injections Placebo
Bright 2021 (68 children) 6.0 and 6.9 cm/year 11.1 cm/year 4.5 cm/year
OraGrowtH210 6.8 to 8.2 cm/year 10.6 cm/year none

The FDA concluded that these results “suggest inferior efficacy compared to approved therapies” (FDA 2024). A growth hormone research society guideline cited by the FDA says oral ghrelin analogs are unlikely to help children with severe pituitary GH deficiency but may have potential in milder forms (FDA 2024). There is no head-to-head trial in adults, for muscle, fat or anything else.

MK-677 vs peptides and other GH secretagogues

WADA puts MK-677 in the same group, growth hormone releasing factors (S2.2.4), as ipamorelin and other GH secretagogues and as GHRH analogs such as CJC-1295 and tesamorelin (WADA 2026). Use the compare tool to put MK-677 next to ipamorelin, CJC-1295 or tesamorelin, or browse the database.

Conclusion

MK-677 and HGH are not interchangeable. HGH is an approved, injected hormone that works even without a functioning pituitary and did better in the only head-to-head trials. MK-677 is an unapproved oral drug that needs your own pituitary, raises GH and IGF-1 and adds some lean mass, with GH-type side effects of its own and a heart-failure signal in frail patients. Neither is legal to sell for non-medical use in the US, and both are banned in sport.

Frequently asked questions

Is MK-677 better than HGH?

No, not on the evidenceEvidence: Trial

In the only head-to-head trials, in children with GH deficiency, GH injections gave faster growth (10.6 to 11.1 cm a year) than ibutamoren (6.0 to 8.2 cm). MK-677 is taken by mouth, but it needs a working pituitary and has never been approved.

Read the full section

How much does MK-677 increase growth hormone?

Mean GH up 97% on 25 mg/dayEvidence: Trial

In older adults, 25 mg/day raised mean 24-hour GH by 97% after two weeks, and after 12 months GH was 1.8 times baseline. It works by enlarging the body's own GH pulses.

Read the full section

Is MK-677 HGH?

NoEvidence: Human data

MK-677 (ibutamoren) is a ghrelin receptor agonist that makes the pituitary release more of the body's own growth hormone. HGH (somatropin) is growth hormone itself.

Read the full section

Is MK-677 safer than HGH?

Not shownEvidence: Trial

They have never been compared for safety. Both cause GH-type side effects such as fluid retention and higher blood sugar, and MK-677 had a heart-failure signal in frail older adults that led the FDA to list it as a significant safety risk.

Read the full section

Sources

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee, 29 October 2024: Ibutamoren Mesylate 2024
  2. ClinicalTrials.gov NCT04614337: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210), posted results 2024
  3. 21 U.S. Code § 333 – Penalties, (e) Prohibited distribution of human growth hormone (Cornell LII) 2026
  4. FDA Warning Letter to an online seller of products marketed as SARMs (MARCS-CMS 719257), 12 December 2025 2025
  5. WADA: The Prohibited List (2026 List, in force from 1 January 2026) 2026
  6. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects 1996 · PMID 8954023
  7. ClinicalTrials.gov NCT06948214: Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency 2026
  8. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial 2008 · PMID 18981485
  9. DEA Diversion Control Division: Controlled Substances – Alphabetical Order (21 October 2026) 2026
  10. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man 1997 · PMID 9349662
  11. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial 2008 · PMID 19015485
  12. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture 2004 · PMID 15066065
  13. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study 2011 · PMID 21067829
  14. Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency 2021 · PMID 33982679